Tags

Type your tag names separated by a space and hit enter

Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
Maturitas. 2006 Oct 20; 55(3):278-87.M

Abstract

OBJECTIVES

Hormone therapy (HT) is associated with a modest, but significantly increased risk for arterial and venous thromboembolism. We have compared the effects of estrogen, tibolone, and raloxifene on relevant markers of coagulation activation and investigated whether there is a dose-response relationship of oral HT.

METHODS

Randomized, open-label, comparative study of 202 healthy women who were assigned to receive treatment for 12 weeks with either low-dose hormone therapy containing 1 mg 17beta-estradiol + 0.5 mg norethisterone acetate (NETA) (n=50), conventional-dose HT containing 2 mg 17beta-estradiol and 1 mg NETA (n=50), 2.5 mg tibolone (n=51), or 60 mg raloxifene (n=51).

RESULTS

The groups were comparable with regard to demographic characteristics and laboratory variables at baseline. D-dimer increased markedly in the conventional-dose HT group, but remained unchanged in the low-dose HT group. Tibolone was associated with a medium increase, whereas raloxifene was associated with a decrease in D-dimer levels. Changes in prothrombin fragment 1 + 2 showed a similar pattern for all four groups, whereas no significant differences in changes of thrombin-antithrombin complex were observed.

CONCLUSIONS

Our data suggest that low-dose HT is associated with less activation of coagulation than conventional-dose HT. This finding may be of clinical importance since randomized clinical trials showing increased risk of thrombosis have utilized conventional-dose HT.

Authors+Show Affiliations

Department of Hematology, Ullevaal University Hospital Trust, Hematological Research Laboratory, NO-0407 Oslo, Norway. a.l.eilertsen@medisin.uio.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16713143

Citation

Eilertsen, A L., et al. "Conventional-dose Hormone Therapy (HT) and Tibolone, but Not Low-dose HT and Raloxifene, Increase Markers of Activated Coagulation." Maturitas, vol. 55, no. 3, 2006, pp. 278-87.
Eilertsen AL, Qvigstad E, Andersen TO, et al. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas. 2006;55(3):278-87.
Eilertsen, A. L., Qvigstad, E., Andersen, T. O., Sandvik, L., & Sandset, P. M. (2006). Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas, 55(3), 278-87.
Eilertsen AL, et al. Conventional-dose Hormone Therapy (HT) and Tibolone, but Not Low-dose HT and Raloxifene, Increase Markers of Activated Coagulation. Maturitas. 2006 Oct 20;55(3):278-87. PubMed PMID: 16713143.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. AU - Eilertsen,A L, AU - Qvigstad,E, AU - Andersen,T O, AU - Sandvik,L, AU - Sandset,P M, Y1 - 2006/05/18/ PY - 2006/01/30/received PY - 2006/04/04/revised PY - 2006/04/11/accepted PY - 2006/5/23/pubmed PY - 2007/1/31/medline PY - 2006/5/23/entrez SP - 278 EP - 87 JF - Maturitas JO - Maturitas VL - 55 IS - 3 N2 - OBJECTIVES: Hormone therapy (HT) is associated with a modest, but significantly increased risk for arterial and venous thromboembolism. We have compared the effects of estrogen, tibolone, and raloxifene on relevant markers of coagulation activation and investigated whether there is a dose-response relationship of oral HT. METHODS: Randomized, open-label, comparative study of 202 healthy women who were assigned to receive treatment for 12 weeks with either low-dose hormone therapy containing 1 mg 17beta-estradiol + 0.5 mg norethisterone acetate (NETA) (n=50), conventional-dose HT containing 2 mg 17beta-estradiol and 1 mg NETA (n=50), 2.5 mg tibolone (n=51), or 60 mg raloxifene (n=51). RESULTS: The groups were comparable with regard to demographic characteristics and laboratory variables at baseline. D-dimer increased markedly in the conventional-dose HT group, but remained unchanged in the low-dose HT group. Tibolone was associated with a medium increase, whereas raloxifene was associated with a decrease in D-dimer levels. Changes in prothrombin fragment 1 + 2 showed a similar pattern for all four groups, whereas no significant differences in changes of thrombin-antithrombin complex were observed. CONCLUSIONS: Our data suggest that low-dose HT is associated with less activation of coagulation than conventional-dose HT. This finding may be of clinical importance since randomized clinical trials showing increased risk of thrombosis have utilized conventional-dose HT. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/16713143/Conventional_dose_hormone_therapy__HT__and_tibolone_but_not_low_dose_HT_and_raloxifene_increase_markers_of_activated_coagulation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5122(06)00132-0 DB - PRIME DP - Unbound Medicine ER -